




Searching News Database: AVONEX
HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
HSMN NewsFeed - 27 Apr 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
HSMN NewsFeed - 30 Jan 2014
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
HSMN NewsFeed - 28 Jan 2013
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
HSMN NewsFeed - 5 Jan 2011
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
HSMN NewsFeed - 7 Jan 2010
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
HSMN NewsFeed - 18 Sep 2008
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
HSMN NewsFeed - 23 Jul 2008
Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
HSMN NewsFeed - 16 Jul 2008
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
HSMN NewsFeed - 20 Oct 2006
AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide, Improves Patient Convenience
AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide, Improves Patient Convenience
HSMN NewsFeed - 29 Sep 2006
AVONEX(R), the #1 Prescribed Multiple Sclerosis (MS) Therapy Worldwide: New MRI Data Presented
AVONEX(R), the #1 Prescribed Multiple Sclerosis (MS) Therapy Worldwide: New MRI Data Presented
HSMN NewsFeed - 20 Jun 2006
AVONEX(R), The Most Prescribed Multiple Sclerosis Therapy Worldwide, May Now Be Given with Smaller Needle
AVONEX(R), The Most Prescribed Multiple Sclerosis Therapy Worldwide, May Now Be Given with Smaller Needle
HSMN NewsFeed - 5 Jun 2006
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
HSMN NewsFeed - 19 May 2006
AVONEX(R), the Most Prescribed Multiple Sclerosis Therapy Worldwide, Celebrates 10th Anniversary
AVONEX(R), the Most Prescribed Multiple Sclerosis Therapy Worldwide, Celebrates 10th Anniversary
HSMN NewsFeed - 28 Apr 2006
CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis
CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis
HSMN NewsFeed - 29 Mar 2006
Mona Haynes Joins Acusphere in Newly Created Position of Vice President, Marketing and Sales
Mona Haynes Joins Acusphere in Newly Created Position of Vice President, Marketing and Sales
HSMN NewsFeed - 21 Feb 2006
IDM and GENESIS Pharma Sign an Exclusive Marketing Agreement for Junovan(TM) in South East Europe
IDM and GENESIS Pharma Sign an Exclusive Marketing Agreement for Junovan(TM) in South East Europe
Additional items found! 46

Members Archive contains
46 additional stories matching:
AVONEX
(Password required)
AVONEX
(Password required)